Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 9, 2013 - Issue 12
Submit an article Journal homepage
227
Views
5
CrossRef citations to date
0
Altmetric
Drug Profile

Certolizumab pegol in axial spondyloarthritis

In-Ho SongCharité Universitätsmedizin Berlin, Medical Clinic I- Rheumatology, Berlin, Germany;Endokrinologikum, Friedrichstraße 76, 10117 Berlin, Germany
&
Martin RudwaleitCharité Universitätsmedizin Berlin, Medical Clinic I- Rheumatology, Berlin, Germany;Endokrinologikum, Friedrichstraße 76, 10117 Berlin, GermanyCorrespondence[email protected]
Pages 1161-1172 | Published online: 10 Jan 2014

References

  • Dougados M, Baeten D. Spondyloarthritis. Lancet 377(9783), 2127–2137 (2011).
  • van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27(4), 361–368 (1984).
  • Rudwaleit M, van der Heijde D, Landewe R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68(6), 777–783 (2009).
  • Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J. How to diagnose axial spondyloarthritis early. Ann. Rheum. Dis. 63(5), 535–543 (2004).
  • Braun J, van den Berg R, Baraliakos X et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70(6), 896–904 (2011).
  • van der Heijde D, Sieper J, Maksymowych W et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70(6), 905–908. (2011).
  • van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582–591 (2005).
  • van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136–2146 (2006).
  • Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230–3236 (2003).
  • Inman RD, Davis JC Jr, Heijde D et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58(11), 3402–3412 (2008).
  • Haibel H, Rudwaleit M, Listing J et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 58(7), 1981–1991 (2008).
  • Barkham N, Keen HI, Coates LC et al. Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 60(4), 946–954 (2009).
  • Song IH, Hermann K, Haibel H et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann. Rheum. Dis. 70(4), 590–596 (2011).
  • Landewe R, Rudwaleit M, Van der Heijde D et al. Effect of certolizumab pegol on signs and symptoms of Ankylosing Spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study. Arthritis Rheum. 64(10 Suppl.), 336–337 (2012).
  • Landewe R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204231 (2013) ( Epub ahead of print).
  • Van der Heijde D, Maksymowych WP, Landewe R et al. Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week Magnetic Resonance Imaging results of a phase 3 double blind randomized placebo-controlled Study. Arthritis Rheum. 64(10 Suppl.), 730 (2012).
  • Van der Heijde D, Braun J, Rudwaleit M, Purcaru O, Kavanaugh A. Increased participation in daily activities after 24 weeks of certolizumab pegol treatment of axial spondyloarthritis patients, including patients with ankylosing spondylitis: results of a phase 3 double-blind randomized placebo-controlled Study. Arthritis Rheum. 64(10 Suppl.), 592 (2012).
  • Sieper J, Kivitz AJ, van Tubergen AM et al. Rapid improvements in patient reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study. Arthritis Rheum. 64(10 Suppl.), 243 (2012).
  • Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 13(11), 1323–1332 (2007).
  • Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68(6), 797–804 (2009).
  • Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319–3329 (2008).
  • Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68(6), 805–811 (2009).
  • Reich K, Ortonne JP, Gottlieb AB et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br. J. Dermatol. 167(1), 180–190 (2012).
  • Schoepfer AM, Vavricka SR, Binek J et al. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn’s disease population: results of the FACTS survey. Inflamm. Bowel Dis. 16(6), 933–938 (2010).
  • Sandborn WJ, Schreiber S, Feagan BG et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin. Gastroenterol. Hepatol. 9(8), 670–678 e673 (2011).
  • Mease P, Fleischmann R, Wollenhaupt J et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis with and without prior Anti-TNF exposure: 24 week results of a phase 3 double-blind randomized placebo-controlled study. Arthritis Rheum. 64(10 Suppl.), 1107 (2012).
  • Fossati G, Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs, including golimumab, in a variety of in vitro assays. Ann. Rheum. Dis. 69( Suppl. 3), 324 (2010).
  • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117(2), 244–279 (2008).
  • Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 10(3), 308–315 (2010).
  • Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 36(1), 3–10 (2005).
  • Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J. Immunol. Methods 348(1–2), 36–41 (2009).
  • Lambert RG, Salonen D, Rahman P et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 56(12), 4005–4014 (2007).
  • Lukas C, Braun J, van der Heijde D et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J. Rheumatol. 34(4), 862–870 (2007).
  • Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). Arthritis Res. Ther. 11(3), R73 (2009).
  • Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. Rheumatology 49(10), 1900–1910 (2010).
  • Kavanaugh A, Smolen JS, Emery P et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum. 61(11), 1592–1600 (2009).
  • Mariette X, Van Vollenhoven R, Bykerk VP et al. Safety update on certolizumab pegol in patients with active rheumatoid arthritis with long term exposure. Arthritis Rheum. 64(10 Suppl.), 221 (2012).
  • Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res. 62(6), 755–763 (2010).
  • Mocciaro F, Renna S, Orlando A, Cottone M. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am. J. Gastroenterol. 104(11), 2867–2868 (2009).
  • Shelling ML, Vitiello M, Lanuti EL, Miteva M, Romanelli P, Kerdel FA. A case of palmoplantar pustulosis induced by certolizumab pegol: new anti-TNF-alpha demonstrates the same class effect. J. Clin. Aesthet. Dermatol. 5(8), 40–41 (2012).
  • Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment. Pharmacol. Ther. 34(11–12), 1318–1327 (2011).
  • Leong J, Fung-Liu B. A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn’s disease. Am. J. Gastroenterol. 105(1), 234 (2010).
  • Pearce F, Johnson SR, Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology 51(3), 578–580 (2012).
  • Schwartzman S, Clark J, Cush JJ. Divergent toxicity of TNF inhibitors on demyelinating disorders and neurological events. Arthritis Rheum. 64(10 Suppl.), 215 (2012).
  • Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int. J. Dermatol. 50(5), 619–625 (2011).
  • Clowse M, Wolf DC, Stach C et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol. Arthritis Rheum. 64(10 Suppl.), 702 (2012).
  • Sieper J, van der Heijde D, Dougados M et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann. Rheum. Dis. 72(6), 815–822 (2013).
  • Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann. Rheum. Dis. 63(6), 665–670 (2004).
  • Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann. Rheum. Dis. 67(9), 1276–1281 (2008).
  • Rudwaleit M, Claudepierre P, Wordsworth P et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J. Rheumatol. 36(4), 801–808 (2009).
  • Lord PA, Farragher TM, Lunt M et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology 49(3), 563–570 (2010).
  • Song IH, Weiss A, Hermann KG et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann. Rheum. Dis. 72(6), 823–825 (2013).
  • Glintborg B, Ostergaard M, Krogh NS et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann. Rheum. Dis. 72(7), 1149–1155 (2013).
  • Kiltz U, Baraliakos X, Karakostas P et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 64(9), 1415–1422 (2012).
  • Rudwaleit M, Haibel H, Baraliakos X et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 60(3), 717–727 (2009).
  • Haroon N, Inman RD, Learch TJ et al. The impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Care Res. 65(10), 2645–2654 (2013).
  • Poddubnyy D, Haibel H, Listing J et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 64(5), 1388–1398 (2012).
  • Baraliakos X, Listing J, von der Recke A, Braun J. The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients. J. Rheumatol. 36(5), 997–1002 (2009).
  • Poddubnyy D, Rudwaleit M, Haibel H et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70(8), 1369–1374 (2011).
  • Bennett AN, McGonagle D, O’Connor P et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 58(11), 3413–3418 (2008).
  • Dougados M, Van der Heijde D, Sieper J et al. Clinical and imaging efficacy of etancerpet in early non-radiographic axial spondyloarthritis: a 12-week, randomized, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 72(Suppl.), 87 (2013).
  • Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12(3), R117 (2010).
  • Lie E, van der Heijde D, Uhlig T et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70(1), 157–163 (2011).
  • Maksymowych WP, Morency N, Conner-Spady B, Lambert RG. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann. Rheum. Dis. 72(1), 23–28 (2013).
  • Song IH, Hermann KG, Haibel H et al. Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann. Rheum. Dis. 70(7), 1257–1263 (2011).
  • Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulted mast cells. Ann. Rheum. Dis. 68( Suppl. 3), 188 (2009).
  • Porter C, Kopotsha T, Smith B, Nesbitt A, Urbaniak S, Armstrong-Fisher S. No significant transfer of certolizumab pegol compared with IgG in the perfused huma placenta in vitro. Ann. Rheum. Dis. 69( Suppl. 3), 210 (2010).
  • Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11(3), 286–292, quiz e24 (2012).
  • Poddubnyy D, Rudwaleit M, Haibel H et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann. Rheum. Dis. 71(10), 1616–1622 (2012).
  • Kroon F, Landewe R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann. Rheum. Dis. 71(10), 1623–1629 (2012).
  • Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-203559 (2013) ( Epub ahead of print).
  • Song IH, Heldmann F, Rudwaleit M et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 62(5), 1290–1297 (2010).
  • Song IH, Heldmann F, Rudwaleit M et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann. Rheum. Dis. 70(6), 1108–1110 (2011).
  • Pathan E, Abraham S, Van Rossen E et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann. Rheum. Dis. 72(9), 1475–1480 (2013).
  • Baeten D, Baraliakos X, Braun J et al. Anti-Interleukin 17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet doi:10.1016/S0140-6736(13)-61134-4 (2013) ( Epub ahead of print).
  • Schneider CK. Biosimilars in rheumatology: the wind of change. Ann. Rheum. Dis. 72(3), 315–318 (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.